Treatment of Diabetes in Patients With Systolic Heart Failure

Completed · Phase 4

Conditions studied: Heart Failure, Systolic, Diabetes Mellitus, Type 2

In brief

Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).

Key facts

Study ID
NCT02920918
Run by
Virginia Commonwealth University
People needed
36
Starts
2016-10-01
Expected to finish
2018-09-01
Last updated by the study team
2019-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.